Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1993 Oct;218(4):571–578. doi: 10.1097/00000658-199310000-00017

Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the esophagus.

J R Stewart 1, S J Hoff 1, D H Johnson 1, M J Murray 1, D R Butler 1, C C Elkins 1, K W Sharp 1, W H Merrill 1, J L Sawyers 1
PMCID: PMC1243021  PMID: 8215648

Abstract

OBJECTIVE: This study sought to determine the impact of preoperative chemotherapy and radiation therapy (neoadjuvant therapy) followed by resection in patients with adenocarcinoma of the esophagus. SUMMARY BACKGROUND DATA: Long-term survival in patients with carcinoma of the esophagus has been poor. An increase in the incidence of adenocarcinoma of the esophagus has been reported recently. METHODS: Fifty-eight patients with biopsy-proven adenocarcinoma of the esophagus treated at this institution from January 1951 through February 1993 were studied. Since 1989, 24 patients were entered prospectively into a multimodality treatment protocol consisting of preoperative cisplatin, 5-fluorouracil (5-FU), and leucovorin with or without etoposide, and concomitant mediastinal radiation (30 Gy). Patients were re-evaluated and offered resection. RESULTS: There were no deaths related to neoadjuvant therapy and toxicity was minimal. Before multimodality therapy was used, the operative mortality rate was 19% (3 of 16 patients). With multimodality therapy, there have been no operative deaths (0 of 23 patients). The median survival time in patients treated before multimodality therapy was 8 months and has yet to be reached for those treated with the neoadjuvant regimen (> 26 months, p < 0.0001). The actuarial survival rate at 24 months was 15% before multimodality therapy and 76% with multimodality therapy. No difference in survival was noted in neoadjuvant protocols with or without etoposide (p = 0.827). CONCLUSIONS: Multimodality therapy with preoperative chemotherapy and radiation therapy followed by resection appears to offer a survival advantage to patients with adenocarcinoma of the esophagus.

Full text

PDF
573

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajani J. A., Roth J. A., Ryan B., McMurtrey M., Rich T. A., Jackson D. E., Abbruzzese J. L., Levin B., DeCaro L., Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990 Jul;8(7):1231–1238. doi: 10.1200/JCO.1990.8.7.1231. [DOI] [PubMed] [Google Scholar]
  2. Blot W. J., Devesa S. S., Kneller R. W., Fraumeni J. F., Jr Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 Mar 13;265(10):1287–1289. [PubMed] [Google Scholar]
  3. Carey R. W., Hilgenberg A. D., Choi N. C., Mathisen D. J., Grillo H. C., Wain J. C., Logan D. L., Bromberg C. A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. Cancer. 1991 Aug 1;68(3):489–492. doi: 10.1002/1097-0142(19910801)68:3<489::aid-cncr2820680307>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  4. Casson A. G., Mukhopadhyay T., Cleary K. R., Ro J. Y., Levin B., Roth J. A. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res. 1991 Aug 15;51(16):4495–4499. [PubMed] [Google Scholar]
  5. Ellis F. H., Jr Treatment of carcinoma of the esophagus or cardia. Mayo Clin Proc. 1989 Aug;64(8):945–955. doi: 10.1016/s0025-6196(12)61222-1. [DOI] [PubMed] [Google Scholar]
  6. Finley R. J., Inculet R. I. The results of esophagogastrectomy without thoracotomy for adenocarcinoma of the esophagogastric junction. Ann Surg. 1989 Oct;210(4):535–543. doi: 10.1097/00000658-198910000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Forastiere A. A., Orringer M. B., Perez-Tamayo C., Urba S. G., Husted S., Takasugi B. J., Zahurak M. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol. 1990 Jan;8(1):119–127. doi: 10.1200/JCO.1990.8.1.119. [DOI] [PubMed] [Google Scholar]
  8. Jankowski J., Coghill G., Hopwood D., Wormsley K. G. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut. 1992 Aug;33(8):1033–1038. doi: 10.1136/gut.33.8.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lerut T., De Leyn P., Coosemans W., Van Raemdonck D., Scheys I., LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg. 1992 Nov;216(5):583–590. doi: 10.1097/00000658-199211000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. MORSON B. C., BELCHER J. R. Adenocarcinoma of the oesophagus and ectopic gastric mucosa. Br J Cancer. 1952 Jun;6(2):127–130. doi: 10.1038/bjc.1952.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. MacFarlane S. D., Hill L. D., Jolly P. C., Kozarek R. A., Anderson R. P. Improved results of surgical treatment for esophageal and gastroesophageal junction carcinomas after preoperative combined chemotherapy and radiation. J Thorac Cardiovasc Surg. 1988 Mar;95(3):415–422. [PubMed] [Google Scholar]
  12. Machover D., Goldschmidt E., Chollet P., Metzger G., Zittoun J., Marquet J., Vandenbulcke J. M., Misset J. L., Schwarzenberg L., Fourtillan J. B. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol. 1986 May;4(5):685–696. doi: 10.1200/JCO.1986.4.5.685. [DOI] [PubMed] [Google Scholar]
  13. Mahoney J. L., Condon R. E. Adenocarcinoma of the esophagus. Ann Surg. 1987 May;205(5):557–562. doi: 10.1097/00000658-198705000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mansour K. A., Downey R. S. Esophageal carcinoma: surgery without preoperative adjuvant chemotherapy. Ann Thorac Surg. 1989 Aug;48(2):201–205. doi: 10.1016/0003-4975(89)90068-4. [DOI] [PubMed] [Google Scholar]
  15. Naef A. P., Savary M., Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975 Nov;70(5):826–835. [PubMed] [Google Scholar]
  16. Orringer M. B., Forastiere A. A., Perez-Tamayo C., Urba S., Takasugi B. J., Bromberg J. Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma. Ann Thorac Surg. 1990 Mar;49(3):348–355. doi: 10.1016/0003-4975(90)90237-z. [DOI] [PubMed] [Google Scholar]
  17. Poon M. A., O'Connell M. J., Moertel C. G., Wieand H. S., Cullinan S. A., Everson L. K., Krook J. E., Mailliard J. A., Laurie J. A., Tschetter L. K. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989 Oct;7(10):1407–1418. doi: 10.1200/JCO.1989.7.10.1407. [DOI] [PubMed] [Google Scholar]
  18. Roth J. A. Molecular surgery for cancer. Arch Surg. 1992 Nov;127(11):1298–1302. doi: 10.1001/archsurg.1992.01420110040010. [DOI] [PubMed] [Google Scholar]
  19. Skinner D. B., Walther B. C., Riddell R. H., Schmidt H., Iascone C., DeMeester T. R. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg. 1983 Oct;198(4):554–565. doi: 10.1097/00000658-198310000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Urba S. G., Orringer M. B., Perez-Tamayo C., Bromberg J., Forastiere A. Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer. 1992 Jan 15;69(2):285–291. doi: 10.1002/1097-0142(19920115)69:2<285::aid-cncr2820690203>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  21. Wang H. H., Antonioli D. A., Goldman H. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum Pathol. 1986 May;17(5):482–487. doi: 10.1016/s0046-8177(86)80038-7. [DOI] [PubMed] [Google Scholar]
  22. Whittington R., Coia L. R., Haller D. G., Rubenstein J. H., Rosato E. F. Adenocarcinoma of the esophagus and esophago-gastric junction: the effects of single and combined modalities on the survival and patterns of failure following treatment. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):593–603. doi: 10.1016/0360-3016(90)90485-3. [DOI] [PubMed] [Google Scholar]
  23. Wolfe W. G., Burton G. V., Seigler H. F., Crocker I. R., Vaughn A. L. Early results with combined modality therapy for carcinoma of the esophagus. Ann Surg. 1987 May;205(5):563–571. doi: 10.1097/00000658-198705000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Yang P. C., Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer. 1988 Feb 1;61(3):612–617. doi: 10.1002/1097-0142(19880201)61:3<612::aid-cncr2820610332>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES